Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 7, Issue 5, 2007, Pages 459-467

  Klok, Rogier M ^a   Al Hadithy, Asmar F Y ^a   van Schayk, Nathalie P J T ^b   Antonisse, Ad J J ^b   Caro, Jaime J ^c   Brouwers, Jacobus R B J ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c CARO RESEARCH INSTITUTE   (United States)

Author keywords

Bipolar disorder; Discrete event simulation; Pharmacoeconomic analysis; Quetiapine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ADJUVANT THERAPY; ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH CARE COST; HEALTH SURVEY; HUMAN; MALE; MENTAL DISEASE; MENTAL HEALTH; MONOTHERAPY; NEGATIVE SYNDROME; NETHERLANDS; PATIENT COMPLIANCE; RECURRENT DISEASE; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 36248983814     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.7.5.459     Document Type: Article

References (31)

1. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness - 1991. Soc. Psychiatry Psychiatr. Epidemiol. 30(5), 213-219 (1995).
2. Bowden CL. Bipolar disorder and work loss. Am. J. Manag. Care 11(Suppl. 3), S91-S94 (2005).
3. Judd LL, Akiskal HS, Schettler PJ et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch. Gen. Psychiatry 62(12), 1322-1330 (2005).
4. Ten Have M, Vollenberg W, Bijl R, Nolen WA. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): results from The Netherlands Mental Survey and Incidence Study (NEMESIS). J. Affect. Disord. 68, 203-213 (2002).
5. Nolen WA, Knoppert-van der Klein EAM, Hunig A et al. Guidelines on Bipolar disorders (In Dutch: Richtlijn bipolaire stoornisen). Nolen WA, Knoppert-van der Klein EAM, Hunig A et al. (Eds), Boom, Amsterdam, The Netherlands (2001).
6. Vieta E. Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 7(Suppl. 4), 21-33 (2005).
7. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol. 15(5), 573-585 (2005).
8. Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled efficay and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Pychiatry 66(1), 111-121 (2005).
9. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder combined analysis of two international, double-blind, placebo-controlled studies. Curr. Med. Res. Opin. 21(6), 923-934 (2005).
10. Sachs G, Chengappa KNR, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomised, double-blind, placebo controlled study. Bipolar Disord. 6, 213-223 (2004).
11. AstraZeneca. Trial 5077IL/0100 Clinical Study Report. A international multicenter, double-blind, randomized, placebo-controlled trial of safety and efficacy of SEROQUEL™ (quetiapine fumerate) as add-on therapy with lithium or divalproex in the treatment of acute mania. December 2002. Data on file.
12. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J. Clin. Psychopharmacol. 24(6), 599-606 (2004).
13. Bijl RV, van Zessen G, Ravelli A. The Netherlands Mental Health Survey and Incidence Study (NEMESIS) objectives and design. Soc. Psychiatry Pychiatr. Epidemiol. 33, 581-586 (1998).
14. de Graaf R, Bijl RV, Beekman ATF, Vollebergh WAM. Temporal sequencing of lifetime mood disorders in relation to co morbid anxiety and substance use disorders; findings from The Netherlands Mental Health Survey and Incidence Study. Soc. Pychiatry Psychiatr. Epidemiol. 38, 1-11 (2003).
15. Banks J, Carson JS, Nelson BL. Discrete Event System Simulation. Englewood Cliffs, NJ, USA (1996).
16. Weinstein MC, O'Brien B, Hornberger J et al. ISPOR Task Force on Good Research Practices - Modelling Studies. Principles of good practice fbr decision analytic modelling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modelling Studies. Value Health 6(1), 9-17 (2003).
17. Cam JJ.Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 23(4),323-332 (2005).
18. Young RC, Biggs JT, Ziegler VE et al. A rating scale for mania: reliability, validity, and sensitivity. Br. J. Psychiatry 133, 429-435 (1978).
19. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH (Eds). Insurance. Dutch Manual an Costing in Economic Evaluations,methods and standard prices for economic evaluations in health care. Foundation for Health Care, Amsterdam, The Netherlands (2004).
20. Tariffbook Medical Specialists (In Dutch: Tariefboek medisch specialisten). College Tarieven Gezondheidszorg, Utrecht. The Netherlands (1999)
21. Jaffe A, Levine J. Antipsychotic medication co prescribing in a large state hospital system. Pharmacoepidemiol. Drug Saf. 12, 41-48 (2003).
22. Strakowski S, DelBello M, Adler C. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 15(9), 701-718 (2001).
23. Namjoshi MA, Rajamannar G, Jacobs T et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J. Affect. Disord. 69(1-3), 109-18 (2002).
24. Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J. Affect. Disord. 81(3), 223-229 (2004).
25. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects, a comprehensive literature review. CNS Drugs 19(Suppl. 1), 1-93 (2005).
26. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia. Drugs 64(20), 2291-2314 (2004).
27. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann. Clin. Psychiatry 14(3), 163-173 (2002).
28. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Pychiatr. Q. 73(4), 297-311 (2002).
29. Perlis RH. The role of pharmacologic treatment guidelines for bipolar disorder. J. Clin. Pychiatry 66(S3), 37-47 (2005).
30. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry 66(S3), 28-36 (2005).
31. Pini S, Abelli M, Cassano GB. The role of quetiapine in the treatment of bipolar disorder. Expert Opin. Pharmacother. 7(7), 929-940 (2006).